Simmiparib is a potent and orally active PARP1 and PARP2 inhibitor with IC50 values of 1.75 nM and 0.22 nM, respectively; it exhibits stronger inhibitory activity against PARP1/2 than its parent compound Olaparib; induces accumulation of DNA double-strand breaks (DSBs) and G2/M arrest, leading to apoptosis in homologous recombination (HR)-deficient cells; demonstrates significant antitumor activity in both cellular and xenograft mouse models.